This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
Top Stock Reports for PayPal, IBM & Fresenius Medical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), International Business Machines (IBM) and Fresenius Medical Care (FMS).
3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1
by Sriparna Ghosal
Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.
Insulet (PODD) Down 7.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Insulet (PODD) Stock Now
by Zacks Equity Research
Investors remain confident in Insulet (PODD) stock on solid prospects.
Insulet Rides on DexCom Pact, Omnipod's Wider Market Reach
by Zacks Equity Research
Insulet (PODD) plans to expand Omnipod DASH across Europe and Canada, further uplifting market sentiment.
Insulet (PODD) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) fourth-quarter 2019 results reflect strong segmental performances.
Insulet (PODD) Lags Q4 Earnings Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -11.11% and 5.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Abbott's Alliance With Insulet to Fortify Diabetic Care Unit
by Zacks Equity Research
Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.
Insulet Partners With Dexcom for Automated Insulin Delivery
by Zacks Equity Research
This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.
Diabetes Management Gains FDA Attention: 3 Stocks in Focus
by Sriparna Ghosal
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Here's Why You Should Hold on to Insulet (PODD) Stock Now
by Zacks Equity Research
Investors can retain Insulet (PODD) stock for now on the back of its solid prospects.
Insulet Rides on Innovation, Omnipod's Wider Market Appeal
by Zacks Equity Research
The full-market commercial launch of Insulet's (PODD) Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System is encouraging.
Why Is Insulet (PODD) Up 14.3% Since Last Earnings Report?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Digital Diabetes Management Gains Momentum: 3 Stocks in Focus
by Trina Mukherjee
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has been gaining from several positive developments recently.
Insulet Rides on Omnipod's Wider Market Reach, New Products
by Zacks Equity Research
Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.
Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
Insulet (PODD) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 200.00% and 7.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More
by Urmimala Biswas
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Why Earnings Season Could Be Great for Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insulet (PODD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY